Skip to main content

Table 1 Savings (vs. null scenario) as a result of implementing universal screening for GBS (NIS at 2010 price levels)

From: Should Israel screen all mothers-to-be to prevent early-onset of neonatal group B streptococcal disease? A cost-utility analysis

TREATMENT COSTS

Marginal

Risk-factor

Universal

Savings

 

Unit costs

Screening

Screening

 

Hospitalization

    

Fatal and non-fatal anaphylaxis

4,301

3,686

20,890

 

Fatality vs. non-GBS

1,997

2,347

968

 

Sepsis vs. non GBS

11,441

419,988

173,336

 

Meningitis & sepsis vs. non-GBS

14,710

59,998

24,762

 

Post-Hospital Care vs. non-GBS

2,130

89,393

36,894

 
  

575,412

256,851

318,561

LTC

    

Deafness

508,260

104,858

43,227

 

Severe Neuro

2,640,519

1,604,008

662,002

 

Moderate Neuro

1,281,790

828,425

341,906

 

Mild Neuro

316,180

216,369

89,299

 
  

2,753,659

908,003

1,617,175

Total Health Service Costs

 

2,775,870

1,136,483

1,935,737

Lifetime productivity losses

 

1,382,007

570,378

811,828

Total Societal Costs

 

4,711,077

1,963,713

2,747,365